Chargement en cours...
Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group
BACKGROUND: Nusinersen is one of an increasing number of new, expensive orphan drugs to receive authorization. These drugs strain public healthcare budgets and challenge principles for resource allocation. Nusinersen was introduced in the Norwegian public healthcare system in 2018. A national expert...
Enregistré dans:
| Publié dans: | BMC Med Ethics |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094497/ https://ncbi.nlm.nih.gov/pubmed/33947377 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12910-021-00623-5 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|